Evaluating the differences among dermatologists' approaches to abnormal laboratory results of patients using oral isotretinoin treatment for acne

Basit Öğe Kaydı
dc.authoridSarikaya Solak, Sezgi/0000-0002-8572-8249
dc.authorwosidSarikaya Solak, Sezgi/A-4789-2016
dc.contributor.authorSolak, Sezgi Sarikaya
dc.contributor.authorYelgen, Hande
dc.contributor.authorBoga, Imran
dc.date.accessioned2024-06-12T10:50:15Z
dc.date.available2024-06-12T10:50:15Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Oral isotretinoin is one of the most frequently used treatment options in moderate and severe acne. Abnormal laboratory results may occur during the treatment and there may be differences in approach to these abnormal laboratory results among dermatologists. Aim: In this study, we aimed to retrospectively evaluate the differences in approach to abnormal laboratory results and treatment modifications of dermatologists during oral isotretinoin treatment. Materials and Methods: Data of 207 patients who had oral isotretinoin treatment for acne between January 2013 and October 2020 were included in this study. Baseline and follow-up laboratory results were reviewed. All treatment modifications were noted and evaluated with relevant literature. Results: Among 207 patients, 28 (13.5%) had treatment modifications due to the abnormal laboratory results, and all of them were due to elevation of lipid and liver enzyme levels. The dose was reduced in 24 (11.6%) patients and the treatment was discontinued in 4 (1.9%) patients. Treatment modification was not compulsory in the vast majority of patients (26 of 28) according to the relevant literature. Conclusion: The results of the present study showed that unnecessary treatment modifications due to the abnormal laboratory results can be made by dermatologists during oral isotretinoin treatment for acne. Educational programs for dermatologists and more detailed guidelines may prevent these unnecessary treatment modifications.en_US
dc.identifier.doi10.4103/tjd.tjd_58_22
dc.identifier.endpage18en_US
dc.identifier.issn1307-7635
dc.identifier.issn1308-5255
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85192246861en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage16en_US
dc.identifier.urihttps://doi.org/10.4103/tjd.tjd_58_22
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17938
dc.identifier.volume17en_US
dc.identifier.wosWOS:000999423000004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofTurk Dermatoloji Dergisi-Turkish Journal Of Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAbnormalen_US
dc.subjectAcneen_US
dc.subjectIsotretinoinen_US
dc.subjectLaboratoryen_US
dc.subjectTreatmenten_US
dc.titleEvaluating the differences among dermatologists' approaches to abnormal laboratory results of patients using oral isotretinoin treatment for acneen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu